Lenalidomide plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia (AML) with recurrent genetic abnormalities- AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM
Acute myeloid leukemia (AML) is a heterogeneous clonal hematopoietic neoplasm. The cytogenetic changes associated with AML impact response rate and survival, and is one of the most important independent prognostic factors. AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM accounts for 1-2% of all forms of AML, and is associated with a younger age at diagnosis, poor response to standard induction chemotherapy, and very poor long-term prognosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Lauren E. Merz, Anthony J. Perissinotti, Bernard L. Marini, Patrick W. Burke, Ashley Crouch, Harry P. Erba, Dale Bixby Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Genetics | Hematology | Leukemia | Lymphoma | Myeloma | Revlimid | Study